Outlook gets approval for LYTENAVA, sees roughly $500 million peak sales by 2030 in wet AMD

 

Outlook Therapeutics wins FDA approval for LYTENAVA, sees roughly $500 million peak sales by 2030 in wet AMD

• Company guides $50–75M in first-year LYTENAVA launch revenue following FDA approval.
• Q3 2026 earnings call guidance assumes 30%–35% share of current wet AMD bevacizumab market.

https://finviz.com/stock?t=OTLK&p=d